Stocks of Allarity Therapeutics Inc. (NASDAQ:ALLR) traded higher last session on Wall Street, down -53.99% to $3.81.
According to the data, Allarity Therapeutics Inc. (NASDAQ:ALLR) has 1 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $8.00, we find $8.00. Given the previous closing price of $8.28, this indicates a potential downside of -3.38 percent. ALLR stock price is now -67.41% away from the 50-day moving average and -99.09% away from the 200-day moving average. The market capitalization of the company currently stands at $1.92M.
A total of 1 analysts have issued a hold rating and 0 have given it a buy rating. Brokers who have rated the stock have averaged $8.00 as their price target over the next twelve months.
A total of 0.71% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALLR stock. In total, there are 11 active investors with 1.70% ownership of the company’s stock.
During the past 12 months, Allarity Therapeutics Inc. has had a low of $5.64 and a high of $3276.00. The fifty day moving average price for ALLR is $11.4102 and a two-hundred day moving average price translates $412.1429 for the stock.
The latest earnings results from Allarity Therapeutics Inc. (NASDAQ: ALLR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$177.2, beating analysts’ expectations of -$315.16 by 137.96. This compares to -$13.01 EPS in the same period last year. The company reported revenue of $3.66 million for the quarter, compared to $18.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -80.02 percent.
Allarity Therapeutics Inc.(ALLR) Company Profile
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
